Lin Shih-Min, Ku Hsiu-Ying, Chang Ting-Chang, Liu Tsang-Wu, Hong Ji-Hong
Department of Radiation Oncology, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
National Health Research Institute, Miaoli, Taiwan.
Oncotarget. 2017 Jul 27;8(49):85203-85213. doi: 10.18632/oncotarget.19617. eCollection 2017 Oct 17.
The importance of the overall treatment time (OTT) has a paradoxical status in the current era of concomitant chemoradiotherapy. The main objective of this nationwide study was to evaluate the correlation between overall treatment duration and clinical outcome in cervical cancer patients treated primarily with curative concurrent chemoradiotherapy (CCRT). In this population-based cohort study, 2,594 patients diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage I-IVA uterine cervical cancer were studied. Univariate and multivariate analyses of prognostic factors were analyzed using Cox's proportional hazards models. The median irradiation duration was 59 days. Significant prognostic factors related to poor cancer-specific survival (CSS) and overall survival (OS) included old age, non-squamous cell cancer type, high-grade histology, increased tumor size, advanced FIGO stage, and prolonged OTT. After multivariate analysis, prolonged treatment time remained as a significant factor for poor CSS (hazard ratio, HR = 1.33; p < 0.001) and OS (HR = 1.15; p = 0.05). Further subgroup analysis showed that the 5-year OS rates after a treatment time of ≤ 56 days compared with > 56 days in patients with FIGO stages I-IIB and III-IVA were 70% and 65% (p = 0.002) compared with 43% and 42% (p = 0.67), respectively. Inconclusion, completion of CCRT within 8 weeks is recommended, particularly for patients with FIGO stage I-IIB disease.
在同步放化疗的当前时代,总治疗时间(OTT)的重要性处于一种矛盾的状态。这项全国性研究的主要目的是评估以根治性同步放化疗(CCRT)为主治疗的宫颈癌患者的总治疗时长与临床结局之间的相关性。在这项基于人群的队列研究中,对2594例被诊断为国际妇产科联盟(FIGO)I-IVA期子宫颈癌的患者进行了研究。使用Cox比例风险模型对预后因素进行单因素和多因素分析。中位照射时长为59天。与较差的癌症特异性生存(CSS)和总生存(OS)相关的显著预后因素包括老年、非鳞状细胞癌类型、高级别组织学、肿瘤大小增加、FIGO分期晚期和OTT延长。多因素分析后,治疗时间延长仍然是CSS差(风险比,HR = 1.33;p < 0.001)和OS差(HR = 1.15;p = 0.05)的一个显著因素。进一步的亚组分析显示,FIGO I-IIB期和III-IVA期患者中,治疗时间≤56天与>56天相比,5年OS率分别为70%和65%(p = 0.002),而在另一种情况(此处原文未明确,推测可能是类似对比但结果不同的另一组情况)下分别为43%和42%(p = 0.67)。总之,建议在8周内完成CCRT,特别是对于FIGO I-IIB期疾病的患者。